Hong Kong stocks surged | Biostar Pharmaceuticals-B (02561.HK) rose more than 6% during trading. The company expects that its product, Longping Growth Promoter, will be approved for domestic market listing in the second half of the year.

According to the Securities Times app, Viiv Healthcare-B (02561.HK) rose more than 6% during intraday trading. As of the time of writing, it had increased by 5.95%, reaching 47.2 Hong Kong dollars, with a trading volume of 1.319 million Hong Kong dollars.